Larix International is excited to present “3rd International meet on Cancer research and drug development” scheduled on February 22nd - 23rd, 2023 in Bangkok, Thailand. This distinguished meet will bring together the Oncology and radiation therapy to discuss and present the newest advances in understanding the Cancers, Diagnosis, Chemotherapy and others
3rd International meet on Cancer research and drug development 2023
Cancer 2023 will feature up-to-date presentations on the Cancer Biology, Pharmaceuticals, Diagnosis and related research updates, evaluation and treatments. New diagnostic tools, drugs, and devices will be reviewed along with their role in specific clinical situations. Integration of guidelines and clinical management will be highlighted. It is an event with evidence-based, guideline-driven update of the critical domains in Drug Development and cancer biology.
Cancer 2023 focusing on the New Research and Treatments. The workshops are designed for academia and industrial benefits who want to have updated knowledge on treatment techniques. The Conference gathers expert Physicians, Doctors and Drug Developers in the world to share their experience and guide participants to explore advanced techniques.
Cancer 2023 invites abstracts related to the new scientific research in all the fields of Cancer, radiation, chemotherapy, drug development and medicines and its related aspects. Registrants are invited to submit an abstract for consideration for oral and poster presentation. In general we encourage more specific to the current research fields representing innovation and recent technologies. Abstracts received will be reviewed by scientific committee from aspirants and categorized as speaker talks and poster presentations.
More content available within our dedicated Learning Zones and Speciality hubs
A detailed look at conditions connected to Oncology.
CDK4/6 inhibitors in breast cancer
Are you familiar with the clinical trial evidence that could help you to select the best cyclin dependent kinase 4/6 (CDK4/6) inhibitor for your metastatic breast cancer patient?
EACCME® accredited module in Early breast cancer and risk stratification
Learn about early breast cancer risk stratification and management